Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary
July 29, 2025
Earnings Call Speaker Segments
Peter Dannenbaum
executiveShirley, thanks — and a good morning to all of you. It's a pleasure to welcome everyone to the Merck & Co, Inc Second Quarter 2025 Conference Call, broadcasting from Rahway, New Jersey, U.S.A. Joining us on this call are Rob Davis, our Chairman and Chief Executive Officer; Caroline Litchfield, our Chief Financial Officer; and Dr. Dean Li, President of Research Labs. Prior to beginning, please note that our GAAP results contain items like acquisition-related charges, restructuring costs, and certain other items, all of which have been excluded from our non-GAAP results. A reconciliation can be found in our press release. Before we go further, I want to note that some of what we say today may fall under the forward-looking statement protections provided by the U.S. Private Securities Litigation Reform Act of 1995's Safe Harbor clause. Such remarks represent what our management currently believes and come with considerable risk and uncertainty. If the assumptions behind them prove wrong, or if those uncertainties come to pass, then actual outcomes may diverge substantially from what those forward-looking statements describe. In our SEC filings—specifically Item 1A within the 2024 10-K—we lay out particular risk factors and cautionary notes that could lead the company's real results to depart materially from anything anticipated in the forward-looking statements we're making this morning. Merck & Co, Inc, which is based in Rahway, New Jersey, in the United States, makes no commitment to revise any forward-looking statements publicly. Throughout today's call, a slide presentation will go along with the prepared remarks of our speakers. The Investor Relations area of our company's website has all of these materials posted, including the slides, the earnings release, today's prepared remarks, and our SEC filings. Having said that, I'll now hand things over to Rob.
Rob Davis
executiveThanks, Peter. Morning, everyone, and I appreciate you being on the call today. We keep making significant strides when it comes to getting our vital medicines and vaccines into the hands of patients and customers, all while pushing our innovative pipeline forward. During the last several months, we've provided a consistent stream of updates demonstrating the robust momentum behind our clinical work, and our growth keeps gaining more from new product launches that are currently rolling out, with additional ones on the way. We've likewise made further moves to strengthen our pipeline. The acquisition of Verona Pharma we announced not long ago stands as yet another instance of us acting with determination when science and value come together, and proceeding with speed to meet our business development goals. My confidence keeps growing that our strategy, rooted in science, will go on creating long-term value for shareholders and for every one of our stakeholders. Now, regarding our second quarter results, we turned in performance that matched what we had anticipated, posting revenue of $15.8 billion. The results show strength in oncology and animal health, plus growing contributions from our new product launches, with WINREVAIR reaching $1 billion in cumulative sales in only a bit more than a year following approval; we anticipate a return to growth during the second half of 2025 and stay confident about our outlook for the rest of the year. I take pride in the concrete progress we're achieving as we broaden and push forward our research program in key therapeutic areas. At this point we're running over 80 phase III studies spanning a variety of therapeutic areas, and we're more and more witnessing the potential we've discussed for a long time, confirmed through positive clinical trial results, registrational filings, and new product launches. These proof points give me rising confidence that we're on course to reach our ambitions. Shifting to some noteworthy recent developments, we reported encouraging top-line results from the initial two phase III trials assessing enlicitide, our oral PCSK9 inhibitor, for treating hyperlipidemia, and for WINREVAIR based on the HYPERION study involving patients recently diagnosed with PAH. On the regulatory side, the FDA approved and the ACIP recommended ENFLONSIA for preventing RSV in infants under eight months old who are born during or entering their first RSV season. We're fully prepared to help families before the coming season arrives. In addition, the FDA has accepted our supplemental BLA for WINREVAIR in PAH along with a new drug application for the fixed-dose combination of doravirine and islatravir to treat HIV. At the IAS conference earlier this month, we showcased new findings from our encouraging HIV pipeline, and we're thrilled about MK-8527, which could potentially become the first once-monthly pill for HIV prevention. We also held an investor event to highlight our HIV programs and the significant commercial opportunity they offer. Our oncology pipeline keeps forging new paths; we celebrated the 10th earlier stage approval for KEYTRUDA and at ASCO shared encouraging data across numerous novel candidates, further strengthening the potential of our portfolio to assist even more patients with cancer. And lastly, with the Verona Pharma acquisition, we gain Ohtuvayre — a first-in-class, novel therapy for chronic obstructive pulmonary disease, or COPD. It fits well with the cardiopulmonary program we're building out, and it speaks to how dedicated we are to transformative science in areas where needs remain largely unmet. Once the deal closes in Q4, we'll put our commercial strengths to work to speed up a successful launch for Ohtuvayre, and we're eager to welcome the Verona Pharma team into our company. Broadly speaking, the progress we keep making gives us encouragement. Every one of these significant milestones serves as a key building block as we head toward a future that's more diversified. As I've noted previously, our company is now entering a phase of swift transformation — one that will bring meaningful impact for patients and for how medicine is practiced — and our excitement about what lies ahead could not be greater. Across the last several years, we've assembled the biggest and broadest pipeline in our company's recent history; we hold more than 20 new and possible future growth drivers, among them the recent successful launches of WINREVAIR and CAPVAXIVE. On top of that, we have many novel late-phase compounds offering potential for considerable patient benefit and blockbuster commercial opportunity. Candidates including enlicitide, tulisokibart, sac-TMT, and MK-3000, among others, stand for potentially profound scientific advances — precisely the kinds of innovations Merck is recognized for. Given the tremendous opportunities in front of us, we're committed to fully investing behind our pipeline, and we'll keep doing so with sharp focus and discipline, for the good of the patients we serve. Earlier today, we announced a multi-year optimization initiative that will redirect investment and resources away from more mature parts of our business and toward our burgeoning array of new growth drivers, further enabling our portfolio's transformation and driving our next chapter of productive, innovation-driven growth. Caroline will give you more detail on that shortly; in short, we're using our scientific expertise to deliver the next wave of innovation capable of saving and improving lives around the world. With every new launch, data readout, and business development transaction, my confidence grows that we can successfully navigate the KEYTRUDA LOE period. I still view the LOE as more of a hill than a cliff, and I'm confident we can grow over the long term. I'd like to thank our talented and dedicated global team for their hard work and their commitment to delivering value for patients, shareholders, and all of our stakeholders; with that, I'll hand the call over to Caroline.
Caroline Litchfield
executiveThank you, Rob, and good morning to everyone. Rob already mentioned that our second-quarter results came in as we had anticipated. Once again, I'm happy to share that the underlying strength of our business is intact, with demand continuing to be robust around the world for our wide-ranging, inventive lineup of products for human and animal health. Thanks to how we execute commercially and operationally, we can create value right now while also putting money into the next wave of innovations and moving our pipeline forward over the long haul to bring value to every stakeholder. Now, moving on to what we delivered in the second quarter: overall company revenues reached $15.8 billion, which is down 2%, both on a reported basis and when you strip out currency effects. As we anticipated, the numbers took a hit from a roughly $1.3 billion drop in GARDASIL sales in China, which cut growth by 9 percentage points. If you set those sales aside, worldwide growth came to 7%, mainly fueled by momentum in oncology and animal health, plus new offerings WINREVAIR and CAPVAXIVE, both of which have gotten off to a fantastic start. The revenue remarks that follow will be given on an ex-exchange basis. Within oncology, KEYTRUDA revenue rose 9%, hitting $8 billion, with gains in the U.S. as well as international markets, powered by strong demand from metastatic indications and greater adoption in earlier-stage cancers. A major driver of that growth came from usage in tumors that mostly affect women, such as certain breast, cervical, and endometrial cancers; on top of that, we saw more use of KEYTRUDA alongside PET/CEF in first-line locally advanced urothelial cancer. We also heard positive things from healthcare providers after the recent launch of a regimen combining KEYTRUDA for certain patients with resectable, locally advanced head and neck cancer, supported by KEYNOTE-689. That marks the first perioperative anti-PD-1 regimen to win approval for treating patients with this disease. Our wider oncology portfolio posted yet another quarter of solid growth. Notably, WELIREG sales climbed 29% to $162 million, largely because of greater use in certain patients in the U.S. with previously treated advanced renal cell carcinoma; over in vaccines, GARDASIL brought in $1.1 billion, down 55%, mostly because of China. Outside China, sales fell 4% as a result of weaker results in Japan, reflecting the end of reimbursement for the catch-up cohort and the timing of public sector purchases in certain international markets. A 2% sales increase in the U.S. came from price and stronger demand, partly offset by CDC purchasing patterns. In pneumococcal, CAPVAXIVE generated $129 million in sales, fueled by demand from retail pharmacies as well as non-retail customers, such as integrated delivery networks and clinics; we continue to be well positioned to help safeguard more adults against invasive pneumococcal disease and to keep driving growth going forward. VAXNEUVANCE sales went up 20%. In the U.S., growth got a boost of about $60 million from CDC stockpile activity, partly offset by competitive pressures. That gain for VAXNEUVANCE was canceled out by a drawdown of CDC stockpile inventory for RotaTeq and VARIVAX, making the transaction net neutral. Beyond the U.S., growth in certain international markets was offset by a competitor's preferential recommendation in Japan. With the latest FDA approval and ACIP recommendation in hand, we're thrilled to begin accepting orders for ENFLONSIA, our monoclonal antibody designed to prevent RSV lower respiratory tract disease in infants heading into their first RSV season. The strong clinical results and ease of use for ENFLONSIA make it a valuable choice for parents and providers alike. We've made significant strides toward the milestones needed to support a successful launch, and we're in a solid position to help safeguard infants against RSV lower respiratory tract disease. In cardiovascular, WINREVAIR maintained its robust trajectory, reaching global sales of $336 million. As Rob mentioned, just 15 months post-launch, cumulative net sales for WINREVAIR have surpassed $1 billion. This milestone speaks to both the difference WINREVAIR makes for patients dealing with pulmonary arterial hypertension and our capacity to combine cutting-edge science with top-tier execution, even in therapeutic areas that are fresh to us. Within the U.S., over 1,600 new patients obtained a prescription in the quarter. We keep observing a consistent rise in the share of new prescriptions for patients whose existing treatments don't include a prostacycline. Beyond the U.S., we're making headway with approvals and reimbursement, such as in Japan, where a launch is anticipated later in the third quarter. All told, the continued rollout of WINREVAIR is living up to our lofty expectations, and we're eager to make a positive difference for more PAH patients. Our animal health segment posted exceptionally strong growth, with sales up 11%. Livestock gains stem from greater demand across every species, plus sales from the aqua portfolio we acquired from Elanco. Companion animal sales growth is driven by price. Progress in both segments also gained from better supply. Now I'll guide you through the rest of our P&L, and my remarks will follow a non-GAAP approach. Gross margin came in at 82.2%, up 1.3 percentage points, fueled by a favorable product mix. Operating expenses rose to $6.6 billion, which includes a $200 million charge tied to the license agreement with Hengrui. Apart from that charge, operating expenses were up 4%, mirroring careful investments backing our strong early and late-phase pipeline, along with essential growth drivers. Other expense totaled $54 million. Our tax rate stood at 15%. All combined, earnings per share reached $2.13. Shifting to our outlook, as Rob pointed out, our company is swiftly advancing toward a future featuring a diverse array of growth drivers, each capable of tackling critical unmet patient needs. We possess an impressive lineup of novel pipeline candidates thanks to our unwavering dedication to innovation and our long-term habit of investing prudently. To make sure we're ideally positioned to seize the numerous opportunities ahead, we've rolled out a multi-year optimization program. Through this portfolio management initiative, we'll be able to channel the full $3 billion in savings realized from slower-growing portions of our operations into areas with greater potential, maximizing the impact of those funds; furthermore, it lets us take advantage of advances in technology to boost productivity and make our operations more efficient. When you add it all up, our total investment is set to keep rising — a sign of the numerous attractive opportunities before us; we believe these steps will put us in a strong position to create value for patients, customers, and shareholders, while also fueling growth over the long term. Now, moving on to our 2025 non-GAAP guidance, we anticipate full-year revenue ranging from $64.3 billion to $65.3 billion. That range reflects growth of 1% to 2%, after excluding an unfavorable foreign exchange effect of roughly 0.5% based on mid-July rates. For gross margin, our assumption stays at approximately 82%. Our guidance for $200 million in tariff-related costs is unchanged, while we await the results of further possible government actions. Operating expenses are now assumed to be between $25.6 billion and $26.4 billion; this range continues to include the $300 million milestone to Lenova for the tech transfer that was completed earlier this month; this guidance does not assume the proposed acquisition of Verona or additional significant potential business development transactions. Other expense is expected to be between $300 million and $400 million. We now assume a full-year tax rate between 15% and 16%; we assume approximately 2.51 billion shares outstanding.
Caroline Litchfield
executiveAll told, our guidance for EPS comes to $8.87 to $8.97. Within that figure sits a roughly $0.15 drag from currency effects, calculated at rates from the middle of July. When you're building out your models, a handful of points deserve attention; our confidence is unchanged regarding the prospects for our launch products and ongoing expansion in oncology and animal health, along with our expected return to growth during the year's second half. Within China, GARDASIL channel inventories are still elevated while demand stays weak. Because of this, shipments into China will stay paused at minimum through the close of this year. Looking at what remains of the year for GARDASIL, Japan is set to become a larger growth obstacle during the second half, since we anniversary the vaccination bump from the 2024 catch-up cohort. On the whole, we anticipate full-year growth for GARDASIL, China aside. Moving on, we anticipate other revenue will come in substantially lower during the year's second half. Although we actively manage currency exposure via our revenue hedging program, at mid-July rates we anticipate a negative effect from those hedges, which shows up in other revenue. Last, we anticipate operating expenses will be divided about equally between the third and fourth quarters, business development expenses aside. Now, shifting to capital allocation, where our approach is the same as before, we will put investments in our business first to fuel near and long-term growth; we will keep funding our innovative pipeline, including kicking off numerous new late-stage clinical trials spanning multiple novel candidates, every one of which could meaningfully tackle significant unmet medical needs. Our dividend commitment stands, with the aim of raising it over time. Business development stays a top priority, as our acquisition of Verona Pharma demonstrates, which we anticipate funding via some mix of cash on hand, commercial paper, and fresh debt issuance; within our solid investment-grade credit rating, we retain the capacity to pursue further science-driven, value-enhancing transactions down the road. Our share repurchase pace carried on, totaling roughly $1.3 billion during the quarter. We anticipate keeping up a comparable level of repurchases in both the third and fourth quarters of 2025, thanks to our strong balance sheet. In closing, we have confidence in our business's outlook, fueled by worldwide demand for our innovative inline portfolio and launches. We hold fast to our commitment to advancing medically significant innovations that will let us deliver value to patients, customers, and shareholders far into the future; with that, I'd like to hand the call over to Dean now.
Dean Li
executiveThanks, Caroline. Morning, everyone. During Q2, we kept witnessing robust momentum throughout the pipeline. Today, I'll go over developments in our cardiopulmonary, infectious diseases, HIV, and oncology programs. To start, regarding the proposed purchase of Verona Pharma. Expanding on the remarks Rob made before, we've tracked the impressive strides made by the Verona team over several years. Ohtuvayre represents the first new mechanism for inhaled maintenance therapy of COPD in over 20 years; it's a dual inhibitor of phosphodiesterase III and IV, offering bronchodilatory and nonsteroidal anti-inflammatory effects. Because of this, it's a key maintenance treatment choice for patients who remain persistently symptomatic. Ohtuvayre is administered to enhance COPD symptoms for improved breathing and to lower the frequency of flare-ups. Phase III trials that looked at Ohtuvayre both as a standalone treatment and in combination with existing background therapies among patients suffering from moderate to severe symptomatic COPD demonstrated clinically meaningful improvements in lung function. Those results provided strong validation, which ultimately resulted in an FDA approval in June 2024. We are eager to complete this acquisition and work alongside the Verona team to advance the ongoing bronchiectasis efforts, while also evaluating potential value in additional indications, combo treatments, and different formulations. Now let's discuss WINREVAIR. Evidence continues to accumulate supporting WINREVAIR's strong clinical benefits across a broad spectrum of patients living with pulmonary arterial hypertension. The phase III HYPERION study, which evaluated WINREVAIR in adults with a new PAH diagnosis, was stopped early after a review of available data from the program. Despite stopping early, the encouraging top-line data we reported last month showed that when WINREVAIR was added to background therapy, there was a substantial reduction in the chance of clinical worsening events compared with background therapy alone. Later this year, a scientific congress will be the venue for presenting the full results. In addition, the FDA granted priority review to a supplemental biologics license application seeking to update WINREVAIR's label based on findings from the phase III ZENITH trial, and it set a PDUFA date of October 25. It's worth noting that ZENITH was the first positive trial in PAH whose primary endpoint consisted solely of major outcome measures, and it was the first phase III study in PAH halted early because efficacy was overwhelming. Caroline Litchfield noted that Japan's Ministry of Health, Labor, and Welfare has given the green light to WINREVAIR. Turning to enlicitide, we shared positive top-line data from two phase III studies — CORALreef heterozygous familial hypercholesterolemia and CORALreef add-on — which tested our once-daily oral PCSK9 inhibitor candidate, developed as a treatment for adults with hyperlipidemia who are already on lipid-lowering therapies, at minimum a statin. It's worth noting that, according to CDC figures, more than 1 million people in the U.S. live with heterozygous familial hypercholesterolemia, while about 86 million adults aged over 20 have high cholesterol. In both studies, the primary endpoint and every key secondary endpoint were met, with patients receiving enlicitide experiencing LDL cholesterol reductions that were statistically significant and clinically meaningful relative to placebo. In-depth results will be shared at upcoming medical meetings. And last, we're very much looking forward to seeing data from the phase III CORALreef Lipids study in the wider hyperlipidemia patient group, and it's a pleasure to share that we've just finished enrolling patients in the phase III CORALreef Outcomes study. Now turning to infectious disease. In the past month, the FDA gave the green light to ENFLONSIA, our long-acting monoclonal antibody that prevents respiratory syncytial virus lower respiratory tract disease in infants who are born during or who are entering their first RSV season. ENFLONSIA stands alone as the first and only option built to protect infants using the same dose no matter what they weigh. The CDC's Advisory Committee on Immunization Practices then cast a vote recommending ENFLONSIA for infants under eight months old during their first RSV season, and also to add this new choice to the Vaccines for Children program, which is a key step toward guaranteeing access. That vote is provisional, and confirmation is still pending. On the vaccines front, we began the first phase III clinical trial of V181, our investigational quadrivalent dengue vaccine. The Mobilized One study is going to assess safety, immunogenicity, and efficacy for a single dose of V181 in preventing dengue disease triggered by any one of the four dengue virus serotypes, no matter what prior exposure a person has had. As the World Health Organization tells us, roughly half the global population now faces dengue risk, and somewhere between 100 million and 400 million infections happen annually. Shifting to HIV, earlier this month we held an investor event that coincided with the International AIDS Society Conference on HIV Science. There, we shared results from a phase II trial of MK-8527, a novel NRTTI candidate under evaluation as an oral choice for HIV pre-exposure prophylaxis. The findings support giving MK-8527 once a month as intended, and that regimen might bring protection quickly—within 60 minutes after taking it—while eliminating the need for a loading dose. Based on this, we have grounds to launch a pair of phase III trials. The first, Express 11, will evaluate how safe and effective MK-8527 is among individuals more likely to be exposed to HIV-1. The second, Express 10, focuses on women and adolescent girls and is being conducted in partnership with the Gates Foundation. In our view, MK-8527 has the potential to serve as a significant new option for people facing elevated HIV risk. During our IAS presentation, we also provided findings regarding the pairing of islatravir — an investigational NRTTI anchor therapy — alongside ulinivirine, which is an investigational NNRTI. Researchers are exploring this combination as a potential once-weekly treatment option for adults living with HIV. The phase II trial, which involves adults whose virus is suppressed, continues to enroll and move forward. Finally, for the fixed-dose combination of doravirine plus islatravir — an investigational once-daily oral two-drug regimen intended for adults living with HIV-1 who have achieved viral suppression on antiretroviral therapy — the FDA has agreed to review the new drug application. April 28, 2026, is the designated target action date. Switching to oncology, at last month's investor event at ASCO, we demonstrated how we've built on our foundational position with KEYTRUDA to assemble a diverse pipeline by successfully carrying out our oncology strategy and moving key pipeline candidates forward. Our broad, differentiated portfolio and pipeline—covering immuno-oncology, precision medicine, and tissue targeting—gives us a unique position to move cancer care forward. Our strategic ambition is to build leading assets across all three of these segments, so that when combination therapies become the norm, our pipeline will be ideally placed to keep transforming how clinical oncology is practiced. When it comes to tissue targeting, we've got three phase III studies now evaluating ifinatamab deruxtecan through our partnership with Daiichi Sankyo: ID8 esophageal O1, which covers unresectable advanced or metastatic esophageal squamous cell carcinoma; ID8 prostate O1, focused on metastatic castrate-resistant prostate cancer; and ID8 lung O2, looking at relapsed small cell lung cancer. Meanwhile, KEYTRUDA continues to deliver strong results and pick up regulatory clearances. Most recently, the FDA gave the green light to use it within a perioperative regimen for a subset of patients who have resectable, locally advanced head and neck squamous cell carcinoma — a decision backed by the KEYNOTE 689 trial. With that, we've reached the 42nd indication and the 10th earlier stage approval for a regimen built on KEYTRUDA. For these patients, catching the disease sooner could lead to better results and reduce how much it weighs on them. Turning to ovarian cancer, we announced favorable progression-free survival and overall survival data for KEYTRUDA combined with chemotherapy, given either with or without bevacizumab, in specific patients, drawing on the phase III KEYNOTE B96 study. No prior regimen built around an immune checkpoint inhibitor has demonstrated a statistically significant overall survival advantage in ovarian cancer — this is the first. We plan to share these results at a medical meeting in the near future. And finally, Japan's Ministry of Health, Labor, and Welfare has granted approval to WELIREG for certain patients facing advanced renal cell carcinoma. As we look toward the second half of this year, we anticipate a number of significant milestones. When it comes to oncology, we have a PDUFA date coming up on September 23rd for subcutaneous pembrolizumab. Over in cardiopulmonary, for WINREVAIR, there's an October 25th PDUFA date tied to the FDA label update that draws on the phase III ZENITH trial, plus we'll present detailed findings from the HYPERION study, and the phase II CADIN study in pulmonary hypertension due to left heart disease reaches its primary completion date in September. As for enlicitide, we'll start sharing detailed phase III results from the CORALreef Development Program at major cardiovascular conferences. And lastly, the Verona Pharma acquisition is set to close in the fourth quarter. I'm eager to share more updates on how we're progressing. With that, I'll hand the call back to Peter.
Peter Dannenbaum
executiveThanks, Dean. Shirley, let's move on to the Q&A portion at this point. So that we can reach as many people with questions as we can, we ask that analysts keep to a single question today. Thanks.
Daina Graybosch
analystHello, and thanks for taking the question. Could you assist us in understanding CADIN, which you mentioned carries a primary completion date in September? More specifically, would you help place the results into context? From what I gather, you have a pair of primary outcomes, or perhaps a primary plus a first secondary, covering PVR along with either a reduction or an improvement in six-minute walk distance. What threshold defines success for each of those? Should those results be repeated in phase III, would they be sufficient to support registration in this HFpEF indication, or would you additionally need to demonstrate an advantage on a hard cardiovascular or mortality endpoint? Thank you.
Dean Li
executiveDaina, many thanks. This is Dean speaking. You're referring to WINREVAIR, correct — we possess a substantial body of data in pulmonary arterial hypertension. The data we are examining beyond pulmonary arterial hypertension sits in CADINs, and it involves a selected heart failure population. This group generally has hemodynamics somewhat more reminiscent of PAH than of other diseases; we are genuinely keen to investigate whether we can expand beyond PAH while concentrating on patients who have heart failure together with a PAH physiology. Regarding the outcomes, you are correct. It's PVR at six minutes. I'd say likely the single most important item, simply because this patient population differs greatly from a PAH population, is that for me the key signal is really the PVR. I believe the six-minute walk will matter as well. For me, it comes down to whether we can achieve a substantial effect on PVR among these patients who do not have PAH. As for the question of whether a phase III would be required, I'd say we will need to see the data. My expectation, before seeing the data, is that I'd imagine the FDA would want a phase III trial in order to truly demonstrate this treatment's effectiveness across this broader patient population.
Peter Dannenbaum
executiveGreat. Thank you, Daina. Next question, please.
Vamil Divan
analystAppreciate you fielding this. I might focus solely on WINREVAIR. Actually, the first item builds on what was asked before, and then I have one of my own. To pick up on the CADIN conversation, I'm not sure whether Dean or somebody else could put a number on that patient population. I realize you said these patients might be somewhat more hemodynamically skewed than what we observe on the pulmonary arterial hypertension side, but some sense of the market size would help, since we keep fielding lots of questions about how to frame the opportunity. My second question, and really my main one, concerns WINREVAIR uptake outside the U.S. There was only a modest bit of growth in the second quarter. I understand you're only now ramping that launch outside the U.S. I'm wondering whether, as a fairly costly product with a recent U.S. launch, your approach outside the U.S. has shifted at all in light of the threat of mostly overnation pricing? Are you reconsidering what pricing you'd be willing to accept for WINREVAIR outside the U.S., or which markets you might prioritize, versus what you thought, say, 1 or 2 years back? Any sense of the broader opportunity outside the U.S. in pulmonary arterial hypertension specifically for WINREVAIR would be helpful. Thank you.
Dean Li
executiveAlright, I'll handle the science one. Regarding Dean and patients with left heart failure — frequently what you see is pulmonary hypertension rather than pulmonary arterial hypertension, caused by elevated pressures within the left heart, commonly assessed through a wedge pressure that subsequently backs up into the pulmonary artery. That isn't the group of patients we care about most; our focus is on those who have heart failure and whose pulmonary hypertension is raised to a rate or degree that's disproportionate relative to their left heart pressures. In a way, when I describe a physiology resembling pulmonary arterial hypertension, that's precisely what this population is, and that's the reason we selected it. As for sizing it, how to dimension it, I'd simply say that to a substantial extent, this dimension goes underdiagnosed within cardiology since no treatment exists for it. Among those patients, the numbers are quite limited. I'd say if you examine estimates without any therapy available for these patients, I think they'll fall in the range of — you know, in the range of pulmonary arterial hypertension plus some factor perhaps higher than that. I genuinely believe that unlike pulmonary arterial hypertension, for which there's quite solid epidemiology, in this physiology here, I'm not sure the epidemiology is as certain, given that no treatment has existed. When frequently no treatment exists, one needs to be somewhat thoughtful about the epidemiology.
Rob Davis
executiveYes, this is Rob speaking. When it comes to the business outside the U.S., generally speaking, and going back to the point you raised, the launch remains at a very early stage. The bulk of reimbursements won't arrive until the second half of this year, and that is the period when growth will truly become visible. Looking at what took place during the quarter, we are in fact seeing contracting in the markets where the drug is being marketed right now, such as Germany. It has gotten off to a solid start. Based on the revenues, there was in fact a pricing adjustment during the quarter, which is the reason things looked flat. Going forward, we still see a substantial opportunity for growth. To put it in context, you may remember that this involves roughly 90,000 patients around the world. Approximately half of those are in the United States. Europe and Japan account for the remaining half. We anticipate — I believe approval in Japan was recently obtained, so that will arrive in the back half of the year. We anticipate wider reimbursement across Europe. Standing here today, it is early, but I would describe things as on track.
Vamil Divan
analystGreat.
Peter Dannenbaum
executiveThanks, Valmel. Next question, please, Shirley.
Analyst
analystThanks a lot for taking that. I'd like to go a bit deeper on the $3 billion restructuring that was announced. From what you said in the press release, my understanding is that the plan is to put all of it back into the business. Given what looks like a big ramp in the pipeline plus the phase III programs coming over the next few years, set against this cost effort, could you help us frame how we ought to think about operating margins or absolute OpEx growth over the coming years? I'm simply attempting to wrap my head around the shape of it, in whatever qualitative way you can offer. Thank you.
Rob Davis
executiveYes, I appreciate that, Chris. Perhaps I'll start with a big-picture response, and then Caroline can add some of the specifics. When you consider what this is really about, as we stand here right now and look at the truly impressive opportunity in front of us with these 20+ launches, we will fully fund those launches, and we need to. On an R&D basis, we need to keep fully funding our phase III pipeline, and we will, in order to make that happen and to keep going, and our spend will grow as time goes on. Our aim is to do that in a productive and efficient way. That's the reason we intend to move money and resources out of the slower growth parts of the business and put them fully into funding the fast-growing parts of our business. Essentially, that $3 billion figure we've talked about represents a reallocation inside our portfolio, shifting from the slow-growing areas toward the faster-growing ones, while we still expect overall growth in spend — ideally, though, at a level that's more productive than what you'd have seen otherwise. As I mentioned, those investments are aimed at our pipeline, ensuring the phase IIIs are fully funded and that we're ready for commercial launch. Caroline may be able to lay out some details.
Caroline Litchfield
executiveRob, I believe you've already done a good job summarizing the main points. As for that chance to save $3 billion, it's going to be achieved by boosting productivity throughout the entire company. The R&D line will feel the effects, along with SG&A and cost of goods. Having said that, every bit of that $3 billion, along with additional spending, will be put back into the business—particularly into R&D, because our pipeline is so strong, and also into SG&A as time goes on while we bring new products to market and aim to stand out with those launches so that we can generate growth over the long term for the company.
Peter Dannenbaum
executiveGreat. Thanks, Chris. Next question, please, Shirley.
Asad Haider
analystThanks for the question. I've got three things on GARDASIL. To start with GARDASIL in the U.S., you mentioned that favorable pricing and demand were partly offset by CDC purchasing, and you acknowledged that CDC purchasing patterns tend to be uneven; over the years, they've also been a meaningful contributor. Could you address how confident you are about the demand trends coming from that channel in today's situation? And regarding the possibility that ACIP could recommend fewer GARDASIL doses in the U.S., could you bring us up to date on how you're viewing the various possible outcomes ahead of the ACIP meetings this fall? Last, on GARDASIL in China, Caroline, I believe you indicated there would be no shipments at least until the close of this year. Any initial perspective on how you're approaching 2026 would be useful. Thank you.
Dean Li
executiveDean here. I'll address the ACIP matter first, then pass the remaining ones over to Caroline and Rob. What the ACIP might decide is not something I can guess at. What I do want to stress is how much faith we have in GARDASIL 9's safety profile and its effectiveness. One point I'd highlight: I believe it has become evident to the ACIP that a distinct gap exists between the rigorous clinical expectations set out by the FDA and the ACIP's own proposals. Regarding a single dose, the FDA has made its position on the elevated evidentiary threshold quite plain. They continue to stress to us efficacy measured against disease endpoints, rather than merely infections, plus data covering both males and females. This gets underlined to us because we're reminded that HPV-related cancers among males are in fact, I believe, now rising above cervical cancer in females; their statistical bar sits very high, and they seek protection durability over a very long term. As for the ACIP, no agenda has been posted for August, September, and October; even so, this subject was deferred, and we expect there will be conversation about it. Our position is unambiguous on safety and efficacy, and on the obvious mismatch between the FDA's elevated evidentiary threshold and whatever data exists so far concerning a single dose.
Caroline Litchfield
executiveWhen it comes to the commercial side, within the U.S., we experienced robust expansion fueled by both price and demand. However, that was largely counterbalanced by the CDC channel, which saw a buy-down during this year's second quarter that exceeded what we observed in Q2 of 2024. Regarding our opportunities for GARDASIL, we do anticipate growth during 2025 and afterward, though that projection doesn't factor in any modification to the U.S. dosing schedule. We'll have to wait and see how things unfold as the ACIP keeps holding those discussions. Turning to China, as mentioned during the prepared remarks, demand is still weak and inventory is still high. We're on the ground doing everything possible to stimulate demand, with females and now with males as well. Having said that, no additional product will be shipped by us this year, and we'll evaluate at year's end what the right schedule ought to be for 2026. I should mention that GARDASIL China now accounts for a sliver of our company, far below 1%; growth isn't something we're relying on from it. What we are relying on are our new products, along with the outstanding execution we deliver on our existing products, to fuel our company's growth in this year's second half and going forward.
Peter Dannenbaum
executiveGreat. Thanks, Asad. Next question, please.
Evan Seigerman
analystHi, everyone. Thanks a lot for taking my question. When you think about business development moving forward, I would really appreciate it if you could elaborate on how you go about diligencing assets when it comes to Chinese versus Western companies. My question is specifically framed around the recent Verona acquisition compared with a recent collaboration that a competitor announced for a Chinese PDE34 inhibitor. Thank you very much.
Dean Li
executiveThis is Dean. We hold a very high standard, regardless of whether something comes from China or from the United States. With respect specifically to what you asked about Verona — I mean, Verona is a company that we have tracked for no less than five years; it always fascinated us, since they had a dual inhibitor of PDE3 and PDE4, with the potential for bronchodilatory and nonsteroidal anti-inflammatory properties. As we observed it, we came to recognize that it could be the first novel mechanism, and today it is the first novel mechanism approved for inhalation for COPD; for us, the fact that it has approval within the United States, and the fact that we have spoken with patients and physicians who use it, leads us to believe it establishes a beachhead, or a groundwork, for this field. Our capacity to move that fast with Verona benefits us, particularly given that we are a company revisiting our roots in cardiopulmonary cardiometabolic; we believe other innovations around this pathway will matter. Holding that first-mover advantage within the United States, and more broadly, is genuinely important. When we examined other assets in this space, specifically those related to China, they were not in that position of a first-mover advantage, which we viewed as critical for Merck to enter the field.
Peter Dannenbaum
executiveExcellent. Appreciate it, Evan. Let's take the following question.
Analyst
analystThank you for fielding my inquiry. It seems to me that a great deal of attention has surrounded the price tag attached to the deal involving your Chinese collaborator on the PD-1 VEGF. What I'd like to know is this: given that the phase I currently underway is open-label, is it fair for us to conclude that all is genuinely proceeding according to schedule, and that you remain able to launch a phase II that could potentially be registrational — something along the lines of a KEYNOTE 21G — within the coming months? Thanks very much.
Dean Li
executiveYes, this is Dean speaking. When it comes to PD-1 VEGF, your understanding is spot on; dual signaling in this particular area has held our attention for quite a while. I'd point to 2018 as the moment our interest began, tied to the wide-ranging collaboration we have with our partners, ASOD. As for the LaNova program specifically, all is unfolding precisely per plan; obviously, we are monitoring the landscape outside our walls as well as data from external sources. Regarding how the LaNova program proceeds from here, that too is progressing exactly as intended — consistent with what was laid out when we first entered into the partnership with LaNova.
Peter Dannenbaum
executiveExcellent. Appreciate it, Umer. Let's take the following question.
Akash Tewari
analystHi there, many thanks. Following a couple of quarters where things dipped somewhat, we're noticing a rise in patient advertising for WINREVAIR. Looking ahead, what would the appropriate tempo be — not just through the remainder of 2025, but honestly 2026 and beyond, given that you now have the HYPERION and ZENITH data? How far along are you when it comes to moving WINREVAIR toward earlier lines of study? Are physicians beginning to embrace this drug more forcefully? Perhaps I could quickly fit in another question; regarding the Hanzo-GLP-1 asset, is it possible to verify that this drug has in fact entered the clinic? Thanks.
Rob Davis
executiveSure, I suppose I can kick things off, and Caroline may want to chime in too. Thanks for asking about WINREVAIR. From what we’re seeing, we’ve been adding around 400 to 500 patients each month quite steadily. I wouldn’t interpret the 1,600 figure for the quarter as indicating any kind of change. It’s actually been quite consistent. We still anticipate that same steady expansion as we continue through the remainder of the year. I believe that addresses the first portion of your question. Caroline, perhaps you could jump back in.
Caroline Litchfield
executiveThe second thing involved our progress when it comes to reaching various groups of patients. Right now, what we see is that 75% of usage goes to individuals receiving triple therapy or who have a prostacyclin as background treatment. That share keeps growing as time goes on. In fact, among the 1,200+ doctors who so far have written prescriptions for WINREVAIR, over 50% of them have prescribed it for people who are either less severe or on dual therapy. This makes us quite confident about what lies ahead, since we will keep serving those with severe disease while also expanding more and more into the less severe population.
Rob Davis
executiveIt seems fair to say that HYPERION and ZENITH are each playing a part in that rising confidence. All of it is progressing the way we had hoped things would when we moved into this area.
Dean Li
executiveI believe it's worth bringing up one thing regarding WINREVAIR — I've spoken with a number of the KOLs at the major center. What's coming, I'd say, is more like a steady flow of useful information rather than any single event. A label update, in my view, would matter a great deal. I also believe a lot of the KOLs have been holding out for the HYPERION data, since it gives them confidence to prescribe earlier in the journey. That will be of real interest to them. Take PAH patients who overlap with connective tissue diseases, for instance. They will want to see how everything comes together across the three trials; both the individual data and the pooled data will matter enormously. Obviously, the ongoing satiria plus the fact that the adverse effects and all of that are well within the label — those things will drive KOL interest in adopting this earlier in the journey and in other patient populations, like connective tissue disease; as for the Hanzo-GLP-1, we stated that they're moving to clinic this year, and everything is on schedule.
Peter Dannenbaum
executiveGreat. Thanks, Akash. Let's take the next question.
Terence Flynn
analystHi there. Appreciate you taking my question. I was curious whether you might share any early thoughts about what a 15% tariff on pharmaceuticals would mean for your 2026 outlook. I understand you won't be providing guidance right now, but I was hoping you could help us frame the possible impact. Do you have any sense of whether this would be introduced gradually over time, or would it come into effect closer to the near term? Thank you.
Rob Davis
executiveYes, Terrence, it's Rob here. Thanks for asking that. Perhaps I'll address the second half of your question first. We still need greater clarity, from the administration as well as more broadly, regarding precisely how this will unfold. It remains unclear how this ties in with the 232 investigation and the timing involved — whether it applies right away or gets phased in pending additional guidance. I'm not in a position to really comment on that. What I can say is that, as we consider — and I don't want to provide 2026 guidance, since we aren't offering forward guidance — as you think about 2025, I'd say that if this took effect right away, the impact would be minimal, given all the efforts we've undertaken on inventory management and relocating our manufacturing into the U.S. Looking ahead, we're in a very strong position to manage that. We've achieved very solid progress even when we consider 2026. We'll provide the detailed guidance as things develop. For 2025, the effect would be minimal.
Peter Dannenbaum
executiveGreat. Thanks, Terrence. Next question, please, Shirley.
Courtney Breen
analystHello, and I really appreciate you fielding this today. To revisit what you said regarding the cost savings initiative and how that money gets shifted around, could you provide some background on what you have in mind for KEYTRUDA — particularly given that this asset is getting closer to the conclusion of its life cycle, and yet plenty of launches are still on the way, plus a subcutaneous product launch is coming? How do you intend to redistribute KEYTRUDA SG&A against the more recent opportunities that require funding, both in R&D and for those new launches? Many thanks.
Rob Davis
executiveYes, Courtney, thanks for asking. When you consider our position in oncology, and perhaps to frame it a bit, I'll address that. Clearly, with KEYTRUDA we've held the top spot in IO therapy. Like we've said all along, our goal is not just to remain the leader and keep that position, but to extend that leadership over the wider set of oncology assets we hold, which, as you're aware, now spans tissue targeting agents and antibody-drug conjugates, and all the small molecules we have — we now have one of the wider pipelines, perhaps the widest, advancing in oncology. Regarding the spend, as you mentioned, we aren't really aiming to reduce oncology spending. We will expand, and the point is to shift resources and supplement them as we begin transitioning from a sole focus on KEYTRUDA toward the wider range of opportunities. You'll observe additional oncology growth spending while KEYTRUDA gets reduced.
Peter Dannenbaum
executiveGreat. Thanks, Courtney. Next question, please, Shirley.
Analyst
analystHello, everyone. I appreciate you taking my question. I have just one, regarding the one big beautiful bill that broadens the orphan drug exclusion under the IRA, and how that impacts when KEYTRUDA might potentially be selected for IRA price cuts. At the time KEYTRUDA first got approved, it had an orphan designation. Roughly 12 months afterward, its first non-orphan indication received approval. Does this one big beautiful bill update essentially move KEYTRUDA's IRA selection from 2028 to 2029? And given that biosimilars would exist by then, would that actually mean KEYTRUDA ends up not being selected for IRA? Thank you.
Rob Davis
executiveYeah, I appreciate that question. Perhaps from a policy standpoint, we strongly back the language that was included in support of orphan drugs. It's been our long-held view that putting investment behind orphan and rare disease matters, and anything more we can do to back that will help patients down the road; so in that respect, we're quite supportive of what the one big beautiful bill put in there. As for your specific question, you're right that KEYTRUDA did launch with an orphan indication in melanoma in 2014. Lung cancer was the first non-orphan indication, in 2015. Going by how the bill reads, the way you've read it, if you examine what's currently in there, that would suggest you'd now expect the drug to be selected for negotiation in 2027, with the negotiated price implemented in 2029. I won't speculate on whether it keeps being included or not when it comes to the loss of exclusivity, the upcoming loss of exclusivity. We'll need to see how that unfolds. I also believe it matters to understand, having said all that, that our focus is on how we grow the business after KEYTRUDA's upcoming loss of exclusivity and push for long-term sustainability in our business. That's where our focus is; this is good, but it doesn't alter that core view of our business.
Peter Dannenbaum
executiveAlright, thank you Trunk. Let's take the next question.
Tim Anderson
analystAppreciate it. I've got a few longer-horizon things to ask Rob. Rob, you keep framing the KEYTRUDA loss as a hill rather than a cliff. Our model agrees with that, yet I don't believe investors or consensus truly buy it. You've stated you're confident growth comes back after that stretch. So two things. Regarding the hill remark, could you remind investors of the largest offsets you currently foresee — how does losing a product that represents 50% of revenues at expiry end up not being a cliff? And second, on your confidence about longer-term growth, can you give us parameters for when that would probably arrive? Our figures show trough revenues in 2031. That's 3 years beyond patent expiry. Roughly speaking, does that strike you as a realistic window for consistent growth to resume?
Rob Davis
executiveYes, Jim, thanks for asking. Honestly, I really welcome it, since this sits at the heart of the valuation case for our company. My personal take is that the street does underappreciate how strong our pipeline really is. As that unfolds, and as I've said repeatedly, as those proof points keep materializing, I'd highlight WINREVAIR first, and we're now seeing it with CAPVAXIVE. Clesrovimab, I believe, will be another. Then we have enlicitide coming, plus sac-TMT. As each of these rolls out, my sense is that confidence will build over time. On your particular question about what we're concentrating on: remember we've provided guidance broadly that we foresee more than $50 billion of potential opportunity across our various therapeutic areas, beginning with oncology — broad-based oncology. At this point we have over 60 phase III clinical studies, I believe, spanning, was it 13 different tumor types, all arriving across the next 5 years. Extremely broad, covering our antibody-drug conjugates and all of the small molecules. There's the individualized neoantigen therapy. I could keep listing them, but those alone, we think, exceed $25 billion. At ASCO we had a chance to start discussing some of that, and we'll keep revealing more as we move forward. Our confidence there stands better today than it did even at ASCO. Each card we turn makes us feel better about what's ahead. Beyond that, look into cardiometabolic. We've pointed to roughly $15 billion in the cardiometabolic space, really with foundational elements originating from WINREVAIR, which we've discussed, and we remain very enthused by what we're seeing there. Enlicitide, our PCSK9 inhibitor, we still consider a huge opportunity. We'll stay focused on what we have in MK-6024, our MASH product. Later this year, I think, we'll see data. We keep feeling very good about that. Across our whole suite in the cardiometabolic space, we feel very good. That accounts for the $15 billion. Ophthalmology, I'd say, is underappreciated, with a multi-billion dollar opportunity. Not long ago we walked through our HIV portfolio, roughly $5 billion of opportunity, and as you know we feel very good about that. The data we hold and where our portfolio is headed matter greatly. Immunology adds another $5 billion, which is important to focus on. Animal Health — look at the growth we posted in Animal Health this quarter. Throughout our long-range plan period, this business is going to grow fast for this company, and it's really built on a new product story, much like the Human Health business. In Europe we just received approval for NUMELVI, our JAK inhibitor for dermatitis. In the United States we just got approval for our injectable, once-annual. Those are the first among multiple new product offerings arriving in that business that will let us more than double it by the time we reach the mid-2030s. All of this leaves out whatever else we'll pursue in business development. The fact that we just completed Ohtuvayre, which brought another multi-billion dollar opportunity that wasn't included in that $50 billion when we stated it, is one more building block being added. There's still plenty for us to do on business development. We've been very clear we aren't stopping. We have an early-stage pipeline, and as we move into 2026 and especially into 2027, you'll increasingly see things emerging from our phase I pipeline into our phase II, which will be visible, and all of it is very exciting. That's why, when I sit and look at where we stand, I feel very good. Naturally, we still have subcutaneous KEYTRUDA, and the base of what we believe the KEYTRUDA business will be, which will let us keep benefiting patients through those offerings. Your characterization is fair. I actually agree with it. As for how quickly we return to growth, I'd say I don't want to get specifics on years, but we've been very clear we want to minimize the clip, which I think we've done. That's why I spoke of the hill, and we want to get back to growth quickly. I do see a path to do that, and I'm confident we will. I think if you revisit the JPM presentation we gave, we had a slide in there representing, if you will, the cone of opportunity within our long-range plan. That sort of gives a profile very similar to what you just described.
Peter Dannenbaum
executivePerfect. Thank you, Tim. I realize we've gone past our scheduled time. There's room for a handful of additional questions. Shirley, let's take the next one, please.
Alex Hammond
analystAppreciate you fielding that. Regarding enlicitide, your team has positioned it as a platform where additional cardiometabolic assets can be layered on. Given that framing, which combos and indications might we see, and at what point should we expect news? Thanks.
Dean Li
executiveYeah, thanks a lot for asking that. Let me just set the stage again — our goal here is for this to become the first oral PCSK9 inhibitor, and beyond simply being first, it's going to be the strongest one when you look at all the competitor data out there; we're expecting it to be the most efficacious oral option for lowering LDL. It ought to carry cardiovascular outcome evidence that's at least comparable — and honestly, we think it might even beat the biologics. Given the data in hand, we acknowledge that among patients with ASCVD, 70% still aren't getting their LDL cholesterol treated, even when they're on statins. If you step back and consider it, LDL represents one axis when it comes to cardiovascular outcomes. With LDL, there are obviously combinations you'd pair with enlicitide to push that response even further. That kind of combo could move ahead rapidly. I also think there's data that keeps evolving here, and we'll likely see it from other players, around things like Lp(a), for instance. In that patient group, if cutting Lp(a) truly turns out to matter for improving cardiovascular outcomes, then think about the potential of an Lp(a) molecule capable of doing that — while also keeping in mind that PCSK9, by inhibiting PCSK9, delivers additional Lp(a) reduction. For patients who have elevated Lp(a), the approach I've taken in treating them is to give them PCSK9. A combination in that setting could be genuinely significant; down the road, other combos tied to other axes — I mentioned LDL, Lp(a) — we'd certainly have interest in inflammatory axes and additional axes used in combination. Enalcitide is a genuinely important molecule. We believe it's one that can act as a platform for driving cardiovascular outcomes forward in increments of 20%, 25%, 30%, and that future has us very excited.
Peter Dannenbaum
executiveGreat. Thanks, Alex. We have time for two more questions, please.
James Shin
analystMorning. Thanks for fitting me in. This one's for Dean. Dean, I know that with MK-2010, everything's tracking to plan, and I'm grateful for that, but did Merck get any word about Cenobiopharm's interest in LaNova? And does that affect at all how Merck views its commitment to 2010, or to developing a PD-1 VEGF5 specific in a broader sense? Thanks.
Dean Li
executiveWhat I'd stress is that our commitment stems from the interest we've had in this space going back to 2018. Nothing about that commitment has shifted. Like I've mentioned, the program we have continues to advance on the schedule we set. As for whether notification happened or didn't, that falls under business development matters we simply don't discuss.
Peter Dannenbaum
executiveThat's right. Excellent. Appreciate it. One more question, if you don't mind.
Mohit Bansal
analystExcellent. Many thanks for fielding my question. My question concerns the guidance. When I look at the guidance on an FX basis against the previous quarter, it appears that the top end of the growth was brought down. I simply wanted to check whether there's any shift in the operational business that we ought to know about. Thank you.
Rob Davis
executiveWe lost your line. My understanding is the question had to do with the reduction. You're seeing a reduction in the guidance, but could you address the guidance, Caroline?
Caroline Litchfield
executiveOkay. For this quarter, our guidance is to keep the revenue midpoint where it is and raise EPS by $0.03. Foreign exchange gave us a quite small tailwind, and that has essentially cancelled out a couple of headwinds. The first one would be a low number of COVID cases over the summer season, which has affected how we see Librio. The second is that an early biosimilar entrant for pembrolizumab has appeared in Argentina, which has affected revenues in that country. With all of that said, we feel confident about our capacity to generate growth in our business this year of between 1% and 2%. If you take out the effect of the China GARDASIL headwind, our underlying growth is between 6% and 8%. We are confident about our future even though an uncertain macro environment does exist for our industry.
Peter Dannenbaum
executiveExcellent. I really appreciate everyone taking the time to ask questions. As is always the case, if anything else comes up, you can reach out to Investor Relations. Thanks so much.
Rob Davis
executiveThank you.
Operator
operatorThat brings an end to the call for today. We appreciate everyone for joining in. Right now, you are free to.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.